Rigel Pharmaceuticals, Inc.
RIGL
$19.41
$0.130.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 169.69% | 115.89% | 62.32% | 55.66% | 57.16% |
| Total Depreciation and Amortization | 79.97% | 55.98% | 35.77% | 14.58% | 24.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 35.05% | 1.38% | -10.62% | -12.52% | -33.21% |
| Change in Net Operating Assets | -98.39% | 31.56% | -18.93% | 106.56% | 132.76% |
| Cash from Operations | 647.99% | 150.10% | 63.09% | 87.20% | 92.21% |
| Capital Expenditure | -- | 86.30% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -62.16% | -72.75% | -82.54% | -87.06% | -71.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 189.29% | -61.23% | -90.51% | -109.76% | -106.30% |
| Cash from Investing | 196.11% | -61.42% | -90.25% | -109.35% | -105.90% |
| Total Debt Issued | -- | -100.00% | -100.00% | -100.00% | 2.09% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 87.23% | -14.20% | -26.60% | -4.05% | -50.61% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -416.91% | -156.07% | 47.41% | 68.14% | 82.59% |
| Cash from Financing | -163.38% | -179.95% | -116.45% | -119.36% | 180.41% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 187.74% | -59.62% | -159.04% | -194.27% | 49.52% |